This is a pharmacokinetic evaluation of lactating women after receiving two doses of Ibrexafungerp. The study population included healthy lactating females who were at least 10 days postpartum with a fully established milk supply and were between the ages of 18 and 50 years at the time of screening

开始日期2023-07-12

申办/合作机构

SCYNEXIS, Inc.

ISRCTN51111674

/ Recruiting临床1期

A phase I, open-label, single-centre study to evaluate the absorption, distribution, metabolism and excretion (ADME) of oral [14C]-ibrexafungerp in healthy male subjects after repeat dosing

开始日期2022-12-15

申办/合作机构-

100 项与枸橼酸艾瑞芬净相关的临床结果

登录后查看更多信息

100 项与枸橼酸艾瑞芬净相关的转化医学

登录后查看更多信息

100 项与枸橼酸艾瑞芬净相关的专利（医药）

登录后查看更多信息

139

项与枸橼酸艾瑞芬净相关的文献（医药）

2026-05-01·CLINICAL MICROBIOLOGY AND INFECTION

Invasive mould infection in children – advances made or obstacles remaining?

Review

作者: Haeusler, Gabrielle M ; Blyth, Christopher C ; Yeoh, Daniel K ; Clark, Julia E ; McMullan, Brendan J ; Slavin, Monica A ; Butters, Coen

BACKGROUND:

Invasive mould infection (IMI) is a major cause of morbidity and mortality in immunocompromised children. Outcomes for paediatric patients with IMI remain poor, due in part to the limitations of available diagnostic tools and therapeutic agents.

OBJECTIVES:

To summarize current and emerging modalities for diagnosis and treatment of IMI in immunocompromised children, focusing on recent advances and remaining barriers.

SOURCES:

A comprehensive literature search of tools for diagnosis and management of IMI in children was conducted using PubMed, including clinical and preclinical studies, relevant consensus guidelines, and reviews.

CONTENT:

Initial diagnosis of IMI, particularly for invasive aspergillosis (IA), often relies on computed tomography imaging of the chest, yet imaging findings are not specific to mould infection and cannot differentiate between IA and nonaspergillus moulds. Fluorodeoxyglucose-positron emission tomography imaging may have advantages, but diagnostic sampling remains essential. Traditional microbiological and histopathological work up of blood, fluid and tissue samples are the mainstay of laboratory diagnosis of IMI in children, yet limitations related to test sensitivity, turnaround time, as well as potential complications associated with invasive sampling remain. Nonculture-based biomarkers, including galactomannan for IA, have a role in diagnosis of paediatric IMI, although interpretation requires consideration of test limitations and patient factors. Molecular assays have shown promise and will be an important diagnostic tool in future. Novel antifungal agents, including isavuconazole, olorofim, fosmanogepix, and ibrexafungerp, have significantly broadened the range of agents with activity against IMI, yet paediatric data are required to facilitate use in children. Similarly, immunotherapeutic approaches have potential to improve outcomes in paediatric IMI, yet data in children remain limited.

IMPLICATIONS:

There has been much progress in IMI management with recent development of novel diagnostic methods, new antifungals, and immunotherapeutic approaches. Ongoing paediatric studies are required to inform optimal implementation of these tools into clinical practice.

2026-04-01·CLINICAL MICROBIOLOGY AND INFECTION

New antifungals for the treatment of invasive mold disease

Review

作者: Aitken, Samuel L ; Rausch, Caitlin R ; McClung, David R ; Vuong, Nancy N

BACKGROUND:

Invasive fungal infections are emerging as a critical threat to healthcare, yet the disparity in development and approval of new antifungal agents has only recently been addressed. In 2022, the WHO published the first global priority list of fungal pathogens (Fungal Priority Pathogens List) in order to promote public health awareness, encourage research and development, and propose actions and strategies for stakeholders to target in combatting the rise of fungal infections.

OBJECTIVES:

This review provides a summary of recent data of recently approved and/or investigational antifungals targeted at invasive mould infections, collating updated information on clinical findings of antifungal agents with potential use or activity against moulds listed on the WHO Fungal Priority Pathogens List.

SOURCES:

A PubMed literature search 'Aspergillus fumigatus', 'Fusarium', 'Mucorales', 'Eumycetoma', 'Scedosporium', and 'Lomentospora' with names of antifungal agents 'rezafungin', 'ibrexafungerp', 'oteseconazole', 'opelconazole', 'fosmanogepix', 'olorofim', 'BAL2062', 'mandimycin', 'ATI-2307', 'MAT2203', 'TFF voriconazole', and 'miltefosine' was conducted.

CONTENT:

Preclinical and clinical trial data published within the last 5 years are discussed. The recent approvals of three new antifungals by the US Food and Drug Administration are a significant accomplishment in the advancement of antifungal therapies. Approvals, current indications, and investigations for rezafungin, ibrexafungerp, and oteseconazole as antimould agents are discussed. Additionally, information on fosmanogepix, opelconazole, and olorofim, as well as reformulated agents and those in the pipeline, is included. Clinical data, where available, were the primary focus of the article.

IMPLICATIONS:

Development of new antifungal agents is challenging because of limited target sites, emergence of resistance, and adverse toxicity profiles. However, clinical data from fosmanogepix, olorofim, and encochleated amphotericin B are promising in both clinical efficacy and safety for the treatment of invasive mould infections. These new agents offer alternative options for difficult-to-treat infections, while providing promising efficacy and improved safety outcomes.

2026-03-01·CLINICAL MICROBIOLOGY AND INFECTION

Optimizing antifungal therapies for Candida infections: evidence, resistance, and emerging approaches

Review

作者: Alguacil-Cuéllar, Laura ; Alastruey-Izquierdo, Ana ; Chen, Sharon C-A ; Halliday, Catriona

BACKGROUND:

Invasive Candida infections are among the most common fungal diseases worldwide, with significant morbidity and mortality in immunocompromised individuals. The increasing prevalence of antifungal resistance in Candida species, particularly non-albicans Candida, complicates clinical management and necessitates novel treatment approaches. The emergence of resistance mechanisms has reduced the efficacy of available antifungal therapies, prompting the need for alternative strategies.

OBJECTIVES:

This manuscript aims to review the primary mechanisms underlying antifungal resistance in Candida species and explore emerging therapeutic strategies, including combination therapies and novel antifungal agents.

SOURCES:

Peer-reviewed literature, clinical guidelines, and recent studies were reviewed to provide a comprehensive overview of antifungal resistance mechanisms, as well as current evidence on novel antifungal agents and combination therapy strategies for the treatment of Candida infections.

CONTENT:

Antifungal resistance in Candida species arises through multiple mechanisms including the overexpression of efflux pumps, reducing intracellular drug concentrations; target site mutations, altering drug binding and efficacy; biofilm formation, providing a physical barrier against antifungals; phenotypic switching and adaptive stress responses; and genomic plasticity, promoting heteroresistance. Emerging therapies include novel antifungals such as rezafungin, ibrexafungerp, and fosmanogepix, as well as combination therapies targeting resistance pathways.

IMPLICATIONS:

The increasing burden of antifungal resistance highlights the need for optimized therapeutic strategies and improved diagnostic tools. Combination therapies and novel antifungals offer promising alternatives, but further research is essential to evaluate their clinical efficacy. Strengthening antifungal stewardship programmes and enhancing surveillance for resistance patterns are critical to managing Candida infections effectively and mitigating the public health threat posed by resistant strains.

234

项与枸橼酸艾瑞芬净相关的新闻（医药）

2026-05-07

·GlobeNewswire-Health Care

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company’s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee’s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended, which was adopted by the Company’s Board of Directors in March 2015 under Rule 5635(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. The inducement awards consist of stock options to purchase 125,000 shares of the Company’s common stock at a per share exercise price of $0.93, the closing price per share of the Company’s common stock as reported by Nasdaq on April 30, 2026, and restricted stock units (“RSUs”) covering 20,000 shares of the Company’s common stock. The employee’s stock options have a vesting commencement date of April 13, 2026, vest over a four-year period, with 25% of the shares underlying the option vesting on the on-year anniversary of the vesting commencement date, and the remaining shares vest in equal monthly installments thereafter over 36 months, subject to the employee’s continued service with the Company. The employee’s RSUs have a vesting commencement date of June 15, 2026, and vest in three equal annual installments over a three-year period, subject to the employee’s continued service through each applicable vesting date. About SCYNEXIS, Inc. SCYNEXIS, Inc. (NASDAQ: SCYX) is dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit www.scynexis.com. CONTACT:Investor RelationsLifeSci Advisors John FrauncesT: 917-355-2395jfraunces@lifesciadvisors.com Source: Scynexis

孤儿药上市批准

2026-05-07

·BioSpace

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - May 6, 2026

JERSEY CITY, N.J., May 06, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (Nasdaq: SCYX) (“SCYNEXIS” or the “Company”), a biotechnology company focused on developing innovative new therapies to address severe rare diseases including SCY-770 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), today announced that on April 30, 2026, the Compensation Committee of the Company’s Board of Directors approved inducement equity awards for a new Vice President in connection with the commencement of employment with the Company. The awards were granted as a material inducement to the employee’s acceptance of employment and were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The awards were granted pursuant to SCYNEXIS’ 2015 Inducement Award Plan, as amended, which was adopted by the Company’s Board of Directors in March 2015 under Rule 5635(c)(4) of the Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company. The inducement awards consist of stock options to purchase 125,000 shares of the Company’s common stock at a per share exercise price of $0.93, the closing price per share of the Company’s common stock as reported by Nasdaq on April 30, 2026, and restricted stock units (“RSUs”) covering 20,000 shares of the Company’s common stock. The employee’s stock options have a vesting commencement date of April 13, 2026, vest over a four-year period, with 25% of the shares underlying the option vesting on the on-year anniversary of the vesting commencement date, and the remaining shares vest in equal monthly installments thereafter over 36 months, subject to the employee’s continued service with the Company. The employee’s RSUs have a vesting commencement date of June 15, 2026, and vest in three equal annual installments over a three-year period, subject to the employee’s continued service through each applicable vesting date. About SCYNEXIS, Inc. SCYNEXIS, Inc. (NASDAQ: SCYX) is dedicated to advancing innovative solutions for severe rare diseases. SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. SCYNEXIS’s proprietary antifungal platform “fungerps” includes BREXAFEMME ® (ibrexafungerp tablets), the first approved representative of this novel class, which has been licensed to GSK, and SCY-247, currently in clinical stages of development. For more information, visit . CONTACT : Investor Relations LifeSci Advisors John Fraunces T: 917-355-2395 jfraunces@lifesciadvisors.com Source: Scynexis

孤儿药上市批准

2026-05-03

·海山风知微生物

耳念珠菌最新研究进展（2025-2026年）

耳念珠菌（Candida auris）作为WHO划定的严重优先级真菌病原体，因多重耐药性、环境高存活力、院内传播能力强、常规方法难鉴定等特征，成为全球感染防控的核心挑战。2025年至2026年5月，全球研究者在耐药机制解析、诊断技术革新、治疗靶点开发、临床循证优化等领域取得多项突破性进展，核心内容梳理如下：一、耐药与毒力机制的突破性新发现本阶段研究突破了传统耐药认知框架，揭示了多条全新的耐药调控通路，同时明确了中国临床分离株的核心耐药特征。1. 液泡钙泵介导的唑类耐药新模型（2026年2月，Nature Microbiology）中国科学院微生物研究所高佳鑫团队联合新加坡ASTAR、同济大学团队，首次揭示液泡钙泵VCX1在氟康唑耐药演化中的核心作用。研究发现，VCX1定位于液泡膜，氟康唑压力下其表达显著上调，通过调控液泡pH与膜电位形成电化学梯度，驱动氟康唑的“液泡区隔化隔离”，大幅降低细胞质内有效药物浓度，颠覆了“外排泵必须直接结合药物”的传统认知。敲除VCX1*可使耳念珠菌对氟康唑敏感性显著提升，该靶点为耐药逆转药物开发提供了全新方向[1]。2. 表观遗传调控枢纽介导的泛耐药机制（2025年5月，Nature Communications）中国科学院上海免疫与感染研究所陈昌斌团队证实，GCN5乙酰转移酶是耳念珠菌唑类耐药的核心表观调控枢纽。GCN5通过乙酰化组蛋白H3，直接激活麦角甾醇合成关键基因ERG11及药物外排泵基因CDR1/MDR1的转录，显著增强唑类耐药性；体外实验证实，GCN5特异性抑制剂CPTH2与棘白菌素类药物联用可显著逆转耐药，协同提升杀菌效果[2]。3. 中国临床分离株耐药谱系的系统解析（2026年4月，BMC Microbiology）国内团队通过全基因组测序（WGS）联合表型实验，首次系统描绘了中国耳念珠菌分离株的遗传背景与耐药图谱。研究证实，国内分离株的核心耐药突变集中于麦角甾醇合成通路ERG11/ERG2/ERG4、外排泵调控基因TAC1B/CDR1；同时发现菌株对医院常用消毒剂耐受性呈两极分化：苯扎氯铵、氯己定、次氯酸钠、乙醇、聚维酮碘仍保持良好杀灭效果，而双十二烷基二甲基氯化铵（DDAC）和过氧化氢的杀灭效能显著下降，为院内消毒方案优化提供了直接依据[3]。4. CO₂感应通路介导的耐药与皮肤定植机制（2026年2月）研究揭示碳酸酐酶Nce103介导的碳酸感应通路（CSP），是耳念珠菌皮肤嗜性和两性霉素B耐药的关键调控通路。Nce103通过转化CO₂维持线粒体能量代谢，支持菌株在营养受限的皮肤环境定植；皮肤共生细菌（奇异变形杆菌、肺炎克雷伯菌）可通过尿素酶释放CO₂，为CSP通路提供底物，进一步增强耳念珠菌的定植能力与耐药性。缺失Nce103可使菌株在大气CO₂浓度下无法生长，且两性霉素B耐药性显著降低[4]。5. GPI锚定蛋白合成的分子基础解析（2026年3月，Protein & Cell）华中科技大学同济医学院于洪军、张敏团队联合张明杰院士团队，首次解析了耳念珠菌GPI转酰胺酶（GPI-T）五亚基复合体的高分辨率结构，明确了其底物识别、催化机制及与人源同源复合体的种属特异性差异。GPI锚定蛋白是真菌细胞壁构建、黏附侵袭、毒力维持的核心分子，该研究为开发高选择性的新型抗真菌药物提供了精准的结构生物学基础[5]。二、新型诊断技术的临床转化进展针对耳念珠菌传统培养鉴定周期长、易误检的痛点，2025-2026年多项快速、精准的诊断技术完成临床效能验证，实现落地转化。1. 国产新型显色培养基的诊断效能验证（2026年1月，《中国感染与化疗杂志》）北京协和医院徐英春、肖盟团队牵头完成了国产耳念珠菌显色培养基（ATAU）的多中心效能验证。研究以MALDI-TOF MS和ITS测序为金标准，纳入184株念珠菌（65株耳念珠菌、114株其他念珠菌）验证，结果显示该培养基可在24h内实现耳念珠菌的特异性显色鉴定，与进口产品性能相当，且成本显著降低，适合基层医疗机构的常规筛查与鉴定[6]。2. 多重实时定量PCR检测系统（2025年4月，ESCMID Global大会）我国丹娜生物研发的MycoMDx耳念珠菌PCR检测系统完成临床验证，该方法可对全血、血浆、血清及各类拭子样本中的耳念珠菌DNA进行定性检测。以真菌培养为金标准，209份临床标本验证显示，该系统检测灵敏度、特异度、重复性均满足临床早期筛查需求，填补了国内合规耳念珠菌核酸快速检测产品的空白[7]。3. 耐药相关突变的快速检测技术2026年2月美国微生物学会（ASM）发表的研究，明确了ERG11的5种核心突变（F126L、K143R、V125/F126L、Y132F、Y501H）与氟康唑耐药、胞内药物蓄积降低的直接关联。基于该研究成果，针对ERG11、FKS1、TAC1B等核心耐药基因的靶向测序Panel已进入临床验证阶段，可在48h内完成菌株耐药表型的预判，指导临床精准用药[8]。三、治疗策略优化与新型药物研发本阶段研究进一步明确了耳念珠菌感染的一线治疗方案，同时多款新型抗真菌药物在耐药株治疗中展现出优异潜力，联合治疗方案的循证证据也持续完善。1. 临床治疗的循证医学更新（2025年6月）一项覆盖34个医疗中心、纳入162例耳念珠菌血流感染患者的国际多中心前瞻性研究，首次系统明确了该疾病的临床特征与治疗结局。研究显示，患者30天全因死亡率高达56.2%，ICU入住、腹腔手术史、血小板减少是死亡的独立危险因素；耐药谱方面，米卡芬净敏感性最高（99.2%，MIC₅₀ 0.12µg/mL），氟康唑耐药率达90.3%，两性霉素B耐药率62.7%，多重耐药（MDR）检出率58.4%。该研究为临床经验性治疗首选棘白菌素类药物提供了高级别循证依据[9]。2. 全球指南的治疗方案更新（2025年6月，ECMM/ISHAM/ASM念珠菌病全球指南）指南明确：耳念珠菌侵袭性感染首选棘白菌素类药物（米卡芬净、卡泊芬净、阿尼芬净）；对于棘白菌素治疗无效或泛耐药菌株，推荐脂质体两性霉素B（LAmB）联合氟胞嘧啶；心内膜炎等深部感染需延长疗程至数周至数月，必要时联合手术清除感染灶。指南同时强调，所有耳念珠菌分离株必须进行全面的药敏试验，避免经验性用药的盲目性[10]。3. 新型抗真菌药物研发进展◦ 艾瑞芬净（Ibrexafungerp）：首个口服葡聚糖合酶抑制剂，可抑制真菌细胞壁β-1,3-D-葡聚糖合成，对携带FKS1突变的棘白菌素耐药株仍保持良好体外活性，目前针对耳念珠菌侵袭性感染的Ⅲ期临床试验正在推进中[11]。◦ 瑞扎芬净（Rezafungin）：新型棘白菌素类药物，半衰期长达130h，可实现每周1次给药，体外实验证实对耳念珠菌野生株及多数耐药株均有强效杀菌活性，药代动力学特征显著优于传统棘白菌素[12]。◦ Fosmanogepix：前体药物，体内转化为活性成分Manogepix后可靶向GWT1酶，抑制真菌GPI锚定蛋白的成熟与转运，对多重耐药耳念珠菌具有广谱抗菌活性，目前已进入Ⅱ期临床研究[13]。4. 耐药逆转的联合治疗方案多项体外及动物实验证实，以下联合方案可显著提升抗真菌疗效、逆转耐药：GCN5抑制剂CPTH2联合棘白菌素类药物、线粒体呼吸链复合物III抑制剂联合两性霉素B、唑类药物联合棘白菌素类药物（无拮抗作用，协同效应最显著）、氟胞嘧啶联合多烯类/棘白菌素类药物[2,14]。四、流行病学与防控策略的关键更新1. 全球流行现状2025年12月《Microbiology and Molecular Biology Reviews》发布的综述显示，全球已有61个国家和地区报告耳念珠菌感染病例，美洲、南亚、欧洲是高发区域，泛耐药菌株的检出率呈逐年上升趋势。WHO已将其列为真菌病原体最高优先级管控名单，是院内感染防控的核心靶标[15]。2. 国内流行与防控进展2026年4月发表的国内多中心研究，首次系统揭示了中国耳念珠菌分离株的克隆传播特征，证实国内流行株以Clade I分支为主，与南亚流行株具有遗传同源性。国家疾控监测数据显示，国内耳念珠菌感染仍以散发病例为主，主要集中于ICU、血液科、老年病科等免疫低下患者集中的科室，尚未出现大规模院内暴发[3]。3. 院内防控优化方案基于消毒剂耐受性的最新研究结果，国内院感专家更新了耳念珠菌院内防控核心建议：环境消毒优先选用含氯消毒剂、乙醇、聚维酮碘、氯己定，不推荐单独使用过氧化氢进行终末消毒；对定植/感染患者严格执行接触隔离，优先单间隔离；对高风险患者开展主动筛查，实现早发现、早隔离、早干预[3,16]。信心指数参考文献[1] Gao J, Li Y, Tan A, et al. Vacuolar calcium pump VCX1 drives fluconazole sequestration and resistance evolution in Candida auris[J]. Nature Microbiology, 2026, 11(2): 342-356. DOI: 10.1038/s41564-025-01687-9.[2] Wang X, Liu H, Zhang Y, et al. GCN5-mediated histone acetylation coordinates azole resistance in Candida auris[J]. Nature Communications, 2025, 16(1): 4287. DOI: 10.1038/s41467-025-58762-3.[3] Zhang L, Wang H, Chen L, et al. Whole-genome sequencing and phenotypic analysis reveal the resistance landscape of clinical Candida auris isolates in China[J]. BMC Microbiology, 2026, 26(1): 78. DOI: 10.1186/s12866-026-02789-5.[4] Munoz JF, Gade L, Chow NA, et al. Carbonic anhydrase Nce103 regulates CO₂ sensing, skin colonization, and amphotericin B tolerance in Candida auris[J]. mBio, 2026, 17(1): e03421-25. DOI: 10.1128/mbio.03421-25.[5] Qing X, Hua Z, Liu J, et al. Structural basis of glycosylphosphatidylinositol transamidase from Candida auris[J]. Protein & Cell, 2026, 17(3): 289-304. DOI: 10.1093/procel/pwac087.[6] 杨欣怡, 陈新飞, 肖盟, 等. 国产新型耳念珠菌显色培养基的诊断效能多中心评价[J]. 中国感染与化疗杂志, 2026, 26(1): 61-71. DOI: 10.16718/j.1009-7708.2025.0196.[7] Li R, Zhang W, Xu Y. Clinical performance evaluation of a novel multiplex real-time PCR assay for rapid detection of Candida auris[C]//35th European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global). Copenhagen, 2025.[8] Lockhart SR, Berkow EL, Jackson BR, et al. Correlation between ERG11 mutations and fluconazole resistance in clinical Candida auris isolates[J]. Journal of Clinical Microbiology, 2026, 64(2): e01892-25. DOI: 10.1128/jcm.01892-25.[9] 胡付品, 王明贵, 徐英春, 等. 耳念珠菌血流感染患者的临床特征与死亡危险因素：一项162例的国际多中心前瞻性研究[J]. 中华临床感染病杂志, 2025, 18(3): 161-168. DOI: 10.3760/cma.j.cn115457-20250412-00034.[10] Cornely OA, Bassetti M, Calandra T, et al. 2025 ECMM/ISHAM/ASM global guideline for the management of candidiasis[J]. Clinical Microbiology and Infection, 2025, 31(Suppl 3): S1-S88. DOI: 10.1016/j.cmi.2025.04.008.[11] Pappas PG, Vazquez JA, Sobel JD, et al. In vitro activity of ibrexafungerp against echinocandin-resistant Candida auris isolates[J]. Antimicrobial Agents and Chemotherapy, 2025, 69(8): e00345-25. DOI: 10.1128/aac.00345-25.[12] Lepak AJ, Andes DR, Zhao M, et al. Pharmacodynamics of rezafungin against Candida auris in a neutropenic murine invasive candidiasis model[J]. Antimicrobial Agents and Chemotherapy, 2025, 69(5): e01987-24. DOI: 10.1128/aac.01987-24.[13] Shaw KJ, Scheinfeldt L, Morrison VA, et al. In vitro activity of fosmanogepix against a global collection of multidrug-resistant Candida auris isolates[J]. Journal of Antimicrobial Chemotherapy, 2025, 80(6): 1589-1596. DOI: 10.1093/jac/dkad127.[14] Lamoth F, Alexander BD. Combination antifungal therapy for invasive Candida auris infections: a systematic review of in vitro, in vivo and clinical evidence[J]. Journal of Fungi, 2025, 11(7): 568. DOI: 10.3390/jof11070568.[15] Chowdhary A, Lionakis MS, Chauhan N. Candida auris: epidemiology, host interactions, antifungal resistance, and diagnostics[J]. Microbiology and Molecular Biology Reviews, 2025, 89(4): e00098-22. DOI: 10.1128/mmbr.00098-22.[16] 中国医院协会医院感染管理专业委员会. 耳念珠菌院内感染防控专家共识（2026版）[J]. 中华医院感染学杂志, 2026, 36(2): 145-152. DOI: 10.11816/cn.ni.2026-251876.

100 项与枸橼酸艾瑞芬净相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D11544	-	J02AX	DB12471

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
外阴阴道念珠菌病	美国	GlaxoSmithKline LLC	2021-06-01
外阴阴道念珠菌病	美国	Glaxosmithkline Plc /Suzhou Mfg. Facility/	2021-06-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
耳念珠菌感染	临床3期	美国	SCYNEXIS, Inc.	2017-11-15
耳念珠菌感染	临床3期	印度	SCYNEXIS, Inc.	2017-11-15
耳念珠菌感染	临床3期	巴基斯坦	SCYNEXIS, Inc.	2017-11-15
耳念珠菌感染	临床3期	南非	SCYNEXIS, Inc.	2017-11-15
念珠菌血症	临床3期	美国	SCYNEXIS, Inc.	2017-11-15
念珠菌血症	临床3期	印度	SCYNEXIS, Inc.	2017-11-15
念珠菌血症	临床3期	巴基斯坦	SCYNEXIS, Inc.	2017-11-15
念珠菌血症	临床3期	南非	SCYNEXIS, Inc.	2017-11-15
变应性支气管肺曲霉菌病	临床3期	美国	SCYNEXIS, Inc.	2017-04-01
变应性支气管肺曲霉菌病	临床3期	奥地利	SCYNEXIS, Inc.	2017-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT06954493 (CTgov)	临床1期	外阴阴道念珠菌病	5	Ibrexafungerp	糧獵鑰醖憲構鹹淵構鬱(鹽繭願壓製選網齋糧顧) = 艱壓網簾蓋膚窪願願築壓廠淵糧廠艱廠壓積憲 (窪廠顧獵壓顧夢繭獵網, 膚顧積憲醖觸繭製築鹽 ~ 簾鑰艱蓋膚選壓壓廠鏇) 更多	-	2025-08-08
NCT03059992 (FURI, CTgov)	临床3期	外阴阴道念珠菌病 \| 球孢子菌病 \| 组织胞浆菌病 ... 更多	233	Ibrexafungerp	襯襯鹽糧遞憲膚觸鬱製(廠廠繭選構鬱餘衊築鬱) = 鹽鹽鹽鹽壓齋製蓋觸鹽繭獵獵鏇鬱鬱簾膚簾鬱 (鏇廠鹽獵醖繭壓範餘餘, 獵襯膚遞遞齋餘鏇築鬱 ~ 顧膚壓糧願鹽鬱選鑰蓋) 更多	-	2024-11-20
CTR20220918 (Pubmed \| Infection) 人工标引	临床3期	外阴阴道念珠菌病	360	IbrexafungerpIbrexafungerp 300 mg	鹹遞廠壓廠網繭製繭鬱(鬱衊憲壓窪衊廠衊築蓋) = 壓遞觸觸鹹願鏇選廠糧製淵膚遞繭繭窪願簾製 (簾襯觸選鹽鏇膚衊繭夢 ) 更多	积极	2024-10-01
				Placebo	鹹遞廠壓廠網繭製繭鬱(鬱衊憲壓窪衊廠衊築蓋) = 蓋齋顧獵鑰範鹹範糧範製淵膚遞繭繭窪願簾製 (簾襯觸選鹽鏇膚衊繭夢 ) 更多
NCT03672292 (SCYNERGIA, CTgov)	临床2期	侵袭性肺曲霉菌病	22	Voriconazole+SCY-078 (SCY-078 Plus Voriconazole)	積餘積網蓋願夢願網憲 = 積壓構淵廠築願淵觸蓋鹹壓醖鑰鑰糧構衊範餘 (觸蓋憲窪衊餘繭衊廠鑰, 鏇鹽鏇蓋糧鑰願糧遞鹹 ~ 鹽積壓鏇選鹽衊鑰範襯) 更多	-	2024-08-09
				Oral Placebo Tablets+Voriconazole (Voriconazole Mono-therapy)	積餘積網蓋願夢願網憲 = 築鏇遞鹹願齋鬱襯築範鹹壓醖鑰鑰糧構衊範餘 (觸蓋憲窪衊餘繭衊廠鑰, 繭鹽範網築願觸膚觸鬱 ~ 糧衊鑰網齋遞築鹹築構) 更多
NCT05399641 (CTgov)	临床3期	外阴阴道念珠菌病	150	Ibrexafungerp (Group A)	醖獵廠夢餘餘膚艱夢艱 = 顧鹹網觸糧齋簾餘鹹鑰鹹遞觸遞構築鑰顧衊夢 (獵鹹範壓鬱壓糧齋鹹繭, 衊襯選鬱顧遞觸製獵鬱 ~ 鏇壓廠鑰觸膚憲鬱膚範) 更多	-	2024-07-10
				Ibrexafungerp (Group B (3 Day Dosing))	醖獵廠夢餘餘膚艱夢艱 = 網觸衊壓鏇醖襯遞餘築鹹遞觸遞構築鑰顧衊夢 (獵鹹範壓鬱壓糧齋鹹繭, 網廠鹽淵獵構獵鏇鬱膚 ~ 夢積窪壓構網糧衊廠餘) 更多
NCT03363841 (CARES, CTgov)	临床3期	耳念珠菌感染 \| 念珠菌血症	30	Ibrexafungerp	遞鏇膚蓋鏇淵壓網淵糧 = 醖築糧襯鹽醖襯艱糧鹹襯窪窪遞製糧鏇積齋構 (壓壓願膚糧蓋蓋鏇選範, 範鹹憲鹹願鹽憲獵鏇網 ~ 膚製繭鹽鏇願願製繭鬱) 更多	-	2024-07-03
NCT02244606 (CTgov)	临床2期	念珠菌血症	27	Ibrexafungerp (Ibrexafungerp 500-mg)	簾築襯糧壓顧餘醖餘選 = 鹽網壓夢網築鹽醖簾鑰鏇願製積觸製壓餘襯憲 (蓋醖鹽獵鏇製醖鹽膚鏇, 繭築壓鹽顧淵網範範積 ~ 醖繭襯構選鹹膚齋鹹構) 更多	-	2024-06-25
				Ibrexafungerp (Ibrexafungerp 750-mg)	簾築襯糧壓顧餘醖餘選 = 糧繭蓋顧選糧鑰選願齋鏇願製積觸製壓餘襯憲 (蓋醖鹽獵鏇製醖鹽膚鏇, 繭夢襯顧鹹鏇網製窪醖 ~ 齋醖糧鏇壓繭顧鹹蓋蓋) 更多
NCT04029116 (CANDLE, CTgov)	临床3期	外阴阴道念珠菌病	440	Fluconazole Tablet+IBREXAFUNGERP (Ibrexafungerp)	觸遞鑰製鬱鹹糧憲衊膚 = 簾鏇選製製構鬱選選齋築遞衊選製鹽夢廠憲簾 (齋壓範簾簾願簾願鑰製, 糧廠糧顧襯襯鑰築鏇窪 ~ 餘鏇積襯網廠糧簾艱窪) 更多	-	2023-06-18
				Placebo oral tablet+Fluconazole Tablet (Placebo)	觸遞鑰製鬱鹹糧憲衊膚 = 窪網壓選鑰積膚憲製膚築遞衊選製鹽夢廠憲簾 (齋壓範簾簾願簾願鑰製, 鹽顧夢廠鏇淵蓋襯顧積 ~ 鹽餘憲糧壓鑰鹹製壓範) 更多
NCT03734991 (VANISH 303 and VANISH 306, Pubmed \| J Womens Health (Larchmt))	临床3期	外阴阴道念珠菌病	376	Ibrexafungerp 300mg BID	製糧憲繭窪壓膚積膚鹽(齋壓網醖蓋襯膚膚糧醖) = 夢蓋壓鑰衊餘選淵顧網簾蓋廠鹹衊製積選淵遞 (顧顧淵觸膚壓糧遞鏇廠 ) 更多	-	2022-10-17
				Placebo	製糧憲繭窪壓膚積膚鹽(齋壓網醖蓋襯膚膚糧醖) = 顧遞網製膚窪壓顧遞鏇簾蓋廠鹹衊製積選淵遞 (顧顧淵觸膚壓糧遞鏇廠 ) 更多
NCT03363841 (CARES, Biospace) 人工标引	临床3期	念珠菌病	18	Ibrexafungerp	窪壓淵網齋艱鹽齋襯遞(鏇鑰膚積鏇鑰蓋積憲獵) = 願獵鹽窪衊簾鑰顧膚蓋膚製鹹艱餘艱廠鏇願鏇 (憲壓鹹範壓製憲餘齋鹽 ) 更多	积极	2022-09-08